Log in to your Inderes Free account to see all free content on this page.

Active Biotech

0.077

SEK

+4.9 %

Less than 1K followers

ACTI

NASDAQ Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview

Financials & Estimates

Ownership

+4.9%

-17.38%

-29.23%

-39.08%

-56.99%

-70.6%

-83.16%

-89.85%

-98.53%

Active Biotech operates in the pharmaceutical industry and focuses on the development of innovative treatments for cancer and autoimmune diseases. The company researches new therapies that can improve patient outcomes and quality of life. The business is global with a primary presence in Europe and North America. Active Biotech was founded in 1998 and is headquartered in Lund, Sweden.

Market cap

94.72M SEK

Turnover

347.11K SEK

Revenue

EBIT %

P/E

Dividend yield-%

Financial calendar

8.5.

2025

Interim report Q1'25

28.5.

2025

General meeting '25

21.8.

2025

Interim report Q2'25

All

Webcasts

Press releases

ShowingAll content types

Press release3/10/2025, 7:30 AM

First patient dosed in the phase II study of tasquinimod in myelofibrosis in the US

Press release2/24/2025, 9:00 AM

First patient enrolled in the HO172 clinical study of tasquinimod in myelofibrosis

Press release2/14/2025, 11:55 AM

Redeye: Active Biotech Q4 2024 - Funded through 2025

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account

Stock market's most popular morning newsletter

Analyst comments and recommendations

Stock comparison tool

PREMIUM account

All company reports and content

Premium tools (e.g. insider transactions & stock screener)

Model portfolio

Regulatory press release2/13/2025, 7:30 AM

Active Biotech Year End Report 2024

Regulatory press release1/31/2025, 7:30 AM

Number of shares and votes in Active Biotech

Press release1/28/2025, 7:30 AM

Active Biotech’s patent for laquinimod in eye disorders granted in the US

Regulatory press release12/30/2024, 7:30 AM

Number of shares and votes in Active Biotech

Regulatory press release12/18/2024, 7:30 AM

Active Biotech's nomination committee appointed

Press release12/9/2024, 7:30 AM

Positive preclinical tasquinimod data in myelofibrosis presented at ASH 2024 now available on Active Biotech’s website

Regulatory press release11/18/2024, 10:30 PM

Active Biotech raises SEK 43.4 million in substantially oversubscribed rights issue including exercise of over-allotment option

Press release11/13/2024, 7:30 AM

Active Biotech’s patent for laquinimod in eye disorders will be granted in the US

Press release11/5/2024, 2:00 PM

Preclinical data of tasquinimod in myelofibrosis to be presented at ASH 2024

Press release10/30/2024, 9:45 AM

Active Biotech’s clinical trial of tasquinimod in myelofibrosis approved in Europe

Regulatory press release10/28/2024, 1:50 PM

Active Biotech publishes prospectus

Regulatory press release10/23/2024, 9:30 AM

Extraordinary General Meeting of Active Biotech AB

Press release10/23/2024, 6:30 AM

European Patent Office has granted Active Biotech’s patent application for eye drop formulation of laquinimod

Press release10/23/2024, 6:21 AM

Redeye: Active Biotech Q3 2024 - Rights Issue Funds Laquinimod

Regulatory press release10/21/2024, 8:30 PM

Active Biotech Interim Report Q3 2024

Regulatory press release10/2/2024, 6:30 AM

Active Biotech adjusts the terms in the announced rights issue

Regulatory press release9/24/2024, 11:00 AM

NOTICE OF EXTRAORDINARY GENERAL MEETING

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.